Volume | 0 |
|
|||||
News | - | ||||||
Day High | Low High |
||||||
Day Low |
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
GreenLight Biosciences Holdings PBC | GRNA | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
0.2995 | 0.2995 |
Trades | Shares Traded | Average Volume | 52 Week Range |
---|---|---|---|
0 | 0 | - | 0.1768 - 0.304 |
Last Trade | Type | Quantity | Price | Currency |
---|---|---|---|---|
- | 0 | US$ 0.2995 | USD |
GreenLight Biosciences Holdings PBC Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
US$ 45.43M | - | - | - | -0.45 |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
GreenLight Biosciences H... News
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical GRNA Price Data
Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
1 Month | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
3 Months | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
6 Months | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
1 Year | 0.269 | 0.304 | 0.1768 | 0.2771112 | 735,467 | 0.0305 | 11.34% |
3 Years | 8.53 | 15.80 | 0.1768 | 2.64 | 444,678 | -8.23 | -96.49% |
5 Years | 8.53 | 15.80 | 0.1768 | 2.64 | 444,678 | -8.23 | -96.49% |
GreenLight Biosciences H... Description
GreenLight Biosciences Inc is a pre-commercial stage synthetic biology company with a proprietary cell-free ribonucleic acid production platform for the discovery, development, and commercialization of high-performing products to promote healthier plants, foods, and people. The company is developing RNA products for plant and life science applications to advance crop management, plant protection, animal health, vaccine development, and pandemic preparation. |